Delivery Order 75N91019D00024-75N91026F00032

The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 24, 2026, with a ceiling value of $17.7 million for clinical material technology development and pilot manufacturing, with ultimate completion on September 23, 2031.

Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with no set-aside applied. The work encompasses development and pilot-scale manufacturing of clinical materials supporting NIAID's research portfolio, building on Leidos Biomedical Research's existing capabilities in bioprocess development, specialized manufacturing including vaccine platforms and gene therapy vectors, and chemistry, manufacturing, and controls development for therapeutic candidates. Leidos Biomedical Research operates as the FFRDC contractor managing the Frederick National Laboratory for Cancer Research campus on behalf of the National Cancer Institute and holds the master indefinite delivery vehicle HHSN261201500003I with NIAID, from which this delivery order flows.